Glenmark Pharmaceuticals

格伦马克制药公司

on Monday said it will launch

周一表示将启动

cancer treatment

癌症治疗

drug

药物

zanubrutinib

泽布替尼

in India following approval by the Drugs Controller General of India (

在印度，经印度药品管理总局批准后 (

DCGI

印度中央药品标准控制局

).

）。

Zanubrutinib will be marketed in India under the brand name

Zanubrutinib 将在印度以品牌名称上市销售

Brukinsa

布鲁金萨

.

。

It is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma.

它是印度首个也是唯一一个获批用于治疗五种不同B细胞恶性肿瘤的布鲁顿酪氨酸激酶（BTK）抑制剂：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、华氏巨球蛋白血症、套细胞淋巴瘤、边缘区淋巴瘤和滤泡性淋巴瘤。

'We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines),' Glenmark Pharmaceuticals President and Business Head - India Formulations Alok Malik said.

“我们期待在未来几个月内作为与百济神州（现为BeOne医药公司）持续合作的一部分，将Brukinsa引入印度市场，”格伦马克制药公司总裁兼印度制剂业务主管阿洛克·马利克表示。

The launch marks a significant milestone in our innovative oncology portfolio, offering patients in India access to a globally trusted therapy with proven efficacy and safety, he added. Glenmark shares on Monday ended 0.68 per cent up at Rs 1,600.85 apiece on BSE.

他表示，此次上市标志着我们在创新肿瘤产品组合中迈出了重要的一步，为印度患者提供了获得全球信赖的、具有已证明的有效性和安全性的疗法。周一，Glenmark股票在BSE收盘时每股上涨0.68％，达到1,600.85卢比。

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)